Literature DB >> 14522016

The function of conserved amino acids in or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan.

Antonio Nakouzi1, Arturo Casadevall.   

Abstract

Most monoclonal antibodies (mAbs) to Cryptococcus neoformans glucuronoxylomannan (GXM) antigen (Ag) are grouped as Class II based on usage of V(H)7183, Vkappa5.1, J(H)2, and Jkappa1 gene elements. Comparative analysis of 43 Class II mAbs revealed conservation of I51, G54, and D61 in heavy-chain variable region (V(H)) complementarity determining region 2 (CDR2), and R95 and D96 in CDR3. Furthermore, position 100b (Kabat numbering scheme) in CDR3 always had an aromatic amino acid (aa) and F was found at position 100c in 96% of mAbs. The function of these conserved residues for binding to GXM and peptide mimetics, and idiotype (Id) structure, was investigated using site-directed mutagenesis. In addition, we mutated W36 and V37 in the second framework. Mutations W36A, Y100bA, and F100cA interfered with antibody (Ab) secretion, but not assembly, and cytoplasmic Ab bound to GXM and Id mAbs. In contrast, mutations V37A, I51A, G54A, and D61A did not affect assembly, secretion, or binding to GXM. Mutating the R95-D96 motif in CDR3 to DR, DD, RR, RA, AD, KD, HD, RE, RN or AA revealed that the positive charge at position 95 was essential for binding GXM, whereas the negative charge at position 96 could be substituted for a non-charged aa. Our results: (1) extend the concept that CDR3 diversity is essential for Ag and Id specificity to a polysaccharide-binding Ab; (2) show that aa conservation in CDRs does not imply a requirement for Ag binding; (3) establish a role for W36 in secretion; and (4) demonstrate that aa motifs used for binding GXM and peptide mimetics can differ.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522016     DOI: 10.1016/s0161-5890(03)00149-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Limiting CDR-H3 diversity abrogates the antibody response to the bacterial polysaccharide α 1→3 dextran.

Authors:  Tamer I Mahmoud; Harry W Schroeder; John F Kearney
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

2.  Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8.

Authors:  Masahide Yano; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-11-10

3.  Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences.

Authors:  Susana Frases; Leonardo Nimrichter; Nathan B Viana; Antonio Nakouzi; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-12-21

4.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

5.  The elastic properties of the Cryptococcus neoformans capsule.

Authors:  Susana Frases; Bruno Pontes; Leonardo Nimrichter; Marcio L Rodrigues; Nathan B Viana; Arturo Casadevall
Journal:  Biophys J       Date:  2009-08-19       Impact factor: 4.033

6.  Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.

Authors:  Soma Rohatgi; Liise-anne Pirofski
Journal:  J Immunol       Date:  2012-11-21       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.